Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C-Reference-Cited by-同舟云学术

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

Published:2014-10-29 Issue:2 Volume:35 Page:429-437
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Nielsen Mette J.¹²,Veidal Sanne S.¹²,Karsdal Morten A.¹²,Ørsnes-Leeming Diana J.¹,Vainer Ben³,Gardner Stephen D.⁴,Hamatake Robert⁴,Goodman Zachary D.⁵,Schuppan Detlef⁶,Patel Keyur⁷

Affiliation:

1. Nordic Bioscience A/S; Herlev Denmark

2. Faculty of Health Science; University of Southern Denmark; Odense Denmark

3. Department of Pathology; Rigshospitalet; Copenhagen University Hospital; Copenhagen Denmark

4. Infectious Diseases Therapeutic Area Unit; GlaxoSmithKline, LLC.; 5 Moore DR RTP NC 27709 USA

5. Hepatic Pathology Consultation and Research; Inova Fairfax Hospital; 3300 Gallows Road Falls Church VA 22042 USA

6. Institute of Translational Immunology; University Medical Center; Johannes Gutenberg University; Mainz Germany

7. Division of Gastroenterology; Duke Clinical Research Institute; Duke University Medical Center; Durham NC USA

Funder

Danish Science Foundation

Danish Agency for Science, Technology and Innovation

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12700/fullpdf

Reference43 articles.

1. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment;Berenguer;J Hepatol,2013

2. Liver biopsy: the best, not the gold standard;Bedossa;J Hepatol,2009

3. Exceeding the limits of liver histology markers;Mehta;J Hepatol,2009

4. An appraisal of the histopathological assessment of liver fibrosis;Standish;Gut,2006

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis;Hepatology Communications;2024-07

2. Clinical significance of procollagen type III N-terminal peptide in patients with alcoholic liver disease;Medical alphabet;2024-05-07

3. Incretin-based investigational therapies for the treatment of MASLD/MASH;Diabetes Research and Clinical Practice;2024-05

4. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis;Hepatology;2024-03-15

5. Biomarcadores séricos para la evaluación de la fibrosis hepática;Advances in Laboratory Medicine / Avances en Medicina de Laboratorio;2024-02-14